ATE227124T1 - Behandlung von multipler sklerose (ms) und anderen demyelinisationserkrankungen unter verwendung von lofepramin in kombination mit l- phenylalamin, tyrosin oder tryptophan und evtl. einer vitamin b12-verbindung - Google Patents

Behandlung von multipler sklerose (ms) und anderen demyelinisationserkrankungen unter verwendung von lofepramin in kombination mit l- phenylalamin, tyrosin oder tryptophan und evtl. einer vitamin b12-verbindung

Info

Publication number
ATE227124T1
ATE227124T1 AT95933488T AT95933488T ATE227124T1 AT E227124 T1 ATE227124 T1 AT E227124T1 AT 95933488 T AT95933488 T AT 95933488T AT 95933488 T AT95933488 T AT 95933488T AT E227124 T1 ATE227124 T1 AT E227124T1
Authority
AT
Austria
Prior art keywords
tyrosine
combination
multiple sclerosis
phenylalamin
lofepramine
Prior art date
Application number
AT95933488T
Other languages
English (en)
Inventor
Cari Loder
Original Assignee
Cari Loder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9420116A external-priority patent/GB9420116D0/en
Priority claimed from GBGB9508482.8A external-priority patent/GB9508482D0/en
Application filed by Cari Loder filed Critical Cari Loder
Application granted granted Critical
Publication of ATE227124T1 publication Critical patent/ATE227124T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fodder In General (AREA)
  • Control Of Indicators Other Than Cathode Ray Tubes (AREA)
  • Control Of El Displays (AREA)
AT95933488T 1994-10-05 1995-10-05 Behandlung von multipler sklerose (ms) und anderen demyelinisationserkrankungen unter verwendung von lofepramin in kombination mit l- phenylalamin, tyrosin oder tryptophan und evtl. einer vitamin b12-verbindung ATE227124T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9420116A GB9420116D0 (en) 1994-10-05 1994-10-05 A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions
GBGB9508482.8A GB9508482D0 (en) 1995-04-26 1995-04-26 A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions, and the product
PCT/GB1995/002361 WO1996011009A1 (en) 1994-10-05 1995-10-05 Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound

Publications (1)

Publication Number Publication Date
ATE227124T1 true ATE227124T1 (de) 2002-11-15

Family

ID=26305745

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95933488T ATE227124T1 (de) 1994-10-05 1995-10-05 Behandlung von multipler sklerose (ms) und anderen demyelinisationserkrankungen unter verwendung von lofepramin in kombination mit l- phenylalamin, tyrosin oder tryptophan und evtl. einer vitamin b12-verbindung

Country Status (19)

Country Link
US (2) US6096737A (de)
EP (1) EP0784476B1 (de)
JP (1) JPH10508583A (de)
AT (1) ATE227124T1 (de)
AU (1) AU710339B2 (de)
CA (1) CA2200761C (de)
CZ (1) CZ293873B6 (de)
DE (1) DE69528773T2 (de)
DK (1) DK0784476T3 (de)
ES (1) ES2184808T3 (de)
FI (1) FI116659B (de)
HU (1) HU225493B1 (de)
IS (1) IS1956B (de)
NO (1) NO314486B1 (de)
NZ (1) NZ293642A (de)
PL (1) PL181802B1 (de)
PT (1) PT784476E (de)
SK (1) SK281932B6 (de)
WO (1) WO1996011009A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0942751B1 (de) * 1996-07-05 2002-09-25 The WWK Trust Zusammensetzungen zur behandlung der peripheren neuropathie, die antidepressiven verbindungen und/oder monoamino-oxidaseinhibitoren und/oder vitamin b12 und/oder neurotransmitter-vorläufer oder induktoren enthalten
GB9617990D0 (en) * 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
EP0835660A1 (de) * 1996-10-14 1998-04-15 Gaston Edmond Filomena Merckx Zusammensetzungen enthaltend Methylcobalamin für die Behandlung von Muliple Sklerosis oder andere demyleinisierende Krankheiten
US7232830B2 (en) * 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
GB9904252D0 (en) * 1999-02-24 1999-04-21 Worsley Andrew P Composition for the treatment of pain
GB9906808D0 (en) * 1999-03-24 1999-05-19 Kilgowan Limited Formulation for treatment of pain
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
CA2774959C (en) * 2000-08-04 2016-05-31 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20020147206A1 (en) * 2001-04-05 2002-10-10 Pfizer Inc. Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US6833142B2 (en) * 2002-03-14 2004-12-21 Duane Bennett Formulation for the prevention and treatment of multiple sclerosis and other demyelinating conditions
US7575929B2 (en) 2002-10-02 2009-08-18 Dmi Life Sciences, Inc. Diagnosis of multiple sclerosis with diketopiperazines
JP2006517969A (ja) * 2003-02-14 2006-08-03 コンビナトアールエックス インコーポレーティッド 免疫炎症性障害の治療のための組み合わせ療法
CN103191409A (zh) 2003-05-15 2013-07-10 Dmi生物科学公司 T-细胞介导的疾病的治疗
GB0313630D0 (en) * 2003-06-12 2003-07-16 Wwk Trust The Compositions for the enhanced treatment of depression
US20050192261A1 (en) * 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
US20110136742A1 (en) * 2006-02-24 2011-06-09 Travis Mickle Antidepressant prodrugs
US8217047B2 (en) * 2008-05-27 2012-07-10 Dmi Acquisition Corp. Therapeutic methods and compounds
WO2011011594A2 (en) * 2009-07-23 2011-01-27 Shriners Hospitals For Children Intracellular toll-like receptors pathways and axonal degeneration
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
CA2846598C (en) 2011-10-10 2019-12-10 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
EP2765968A4 (de) 2011-10-10 2015-01-21 Ampio Pharmaceuticals Inc Implantierbare medizinprodukte mit erhöhter immuntoleranz sowie verfahren zur herstellung und implantation
HK1198812A1 (en) 2011-10-28 2015-06-12 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
EA201500943A1 (ru) 2013-03-15 2016-08-31 Ампио Фармасьютикалс, Инк. Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов
CA2958080A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
WO2017085437A1 (en) 2015-11-19 2017-05-26 The Wwk Trust Combinations for the treatment of dementia, and the enhancement of cognitive function
US20190262353A1 (en) * 2016-10-25 2019-08-29 Uti Limited Partnership Treatment for progressive multiple sclerosis
WO2018200381A1 (en) 2017-04-25 2018-11-01 Temple Otorongo Llc Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
EP3431491A1 (de) * 2017-07-18 2019-01-23 Centre National De La Recherche Scientifique Verfahren zur reinigung von proteinen mit einer tubulin-carboxypeptidase-aktivität und peptidbasierten inhibitoren davon

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1497306A (en) * 1975-07-03 1978-01-05 Leo Ab Preparation of lofepramine and its hydrochloride
GB2082910A (en) * 1980-08-28 1982-03-17 Berk Pharmaceuticals Ltd Anti-depressant compositions
US4409243A (en) * 1981-11-09 1983-10-11 Julian Lieb Treatment of auto-immune and inflammatory diseases
GB2129299A (en) * 1982-11-09 1984-05-16 Alec James Coppen Pharmaceutical compositions
DE3519687A1 (de) * 1985-06-01 1986-12-04 Veit Arend Aminosaeuren enthaltendes arzneimittel
US4650789A (en) * 1985-10-15 1987-03-17 Commonwealth Medical Corporation Of America Method and composition for increasing production of serotonin
US4843071A (en) * 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
DE4204102C2 (de) * 1992-02-12 1998-09-24 Kragler Peter Arzneimittel zur Behandlung und/oder Prophylaxe von AIDS und anderen verwandten Erkrankungen

Also Published As

Publication number Publication date
PT784476E (pt) 2003-03-31
JPH10508583A (ja) 1998-08-25
AU3612695A (en) 1996-05-02
FI971290L (fi) 1997-06-02
CA2200761A1 (en) 1996-04-18
US6096737A (en) 2000-08-01
NO971539L (no) 1997-04-04
DE69528773T2 (de) 2003-09-04
ES2184808T3 (es) 2003-04-16
NZ293642A (en) 1998-10-28
NO314486B1 (no) 2003-03-31
PL319830A1 (en) 1997-09-01
NO971539D0 (no) 1997-04-04
DE69528773D1 (de) 2002-12-12
WO1996011009A1 (en) 1996-04-18
CA2200761C (en) 2008-02-26
EP0784476A1 (de) 1997-07-23
CZ99597A3 (en) 1997-11-12
FI116659B (fi) 2006-01-31
AU710339B2 (en) 1999-09-16
SK281932B6 (sk) 2001-09-11
PL181802B1 (en) 2001-09-28
FI971290A0 (fi) 1997-03-26
HU225493B1 (en) 2007-01-29
US6569850B1 (en) 2003-05-27
DK0784476T3 (da) 2003-03-17
HUT77380A (hu) 1998-04-28
IS1956B (is) 2004-11-15
CZ293873B6 (cs) 2004-08-18
IS4454A (is) 1997-03-26
EP0784476B1 (de) 2002-11-06
SK43897A3 (en) 1998-08-05

Similar Documents

Publication Publication Date Title
ATE227124T1 (de) Behandlung von multipler sklerose (ms) und anderen demyelinisationserkrankungen unter verwendung von lofepramin in kombination mit l- phenylalamin, tyrosin oder tryptophan und evtl. einer vitamin b12-verbindung
DE69428523D1 (de) Verfahren zur behandlung von gemüts- oder geisteskrankheiten und von gemüts- oder geisteskrankheiten, die von anfällen begleitet sind
BR0111898A (pt) Métodos de tratamento de doenças de proliferação celular, e de um distúrbio associado com a atividade de cinesina ksp, método de inibição da cinesina ksp, composto, método de triagem de moduladores da cinesina kps, e, método de triagem de compostos que se ligam à cinesina ksp
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69434211D1 (de) Phenylacetate und derivate, allein oder in kombination mit anderen verbindungen, zur behandlung von neoplastischen und anderen erkrankungen
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DK0646012T3 (da) Sårheling og behandling af fibrotiske sygdomme ved hjælp af TGFbeta-3
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
ATE93138T1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
ATE252897T1 (de) Verwendung von p-aminophenolderivaten zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von neurodegenerativen erkrankungen
ATE225177T1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE216891T1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
DK0858341T3 (da) Kombinationsbehandling af fremskreden cancer omfattende temozolomid og cisplatin
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ES2183977T3 (es) Combinacion de temozolomida y alfa-interferon para el tratamiento de cancer avanzado.
NO984198L (no) FremgangsmÕte for behandling av aggresjon

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0784476

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee